The aim of this study was to compare percutaneous aortic valve replacement (TAVR) with the self-expanding Valve Core with conventional surgery in patients at high surgical risk. Patients with a valve area < 0.8 cm2 , valvular index ≤ 0.5 cm2 , a mean gradient of > 40 mmHg or peak speeds above 4m /s...
Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at 12 months as reported in the PARTNER study, which demonstrated a reduction in mortality and an improvement in the quality of life for patients. However, the long term benefit of this...
Original title: Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation. Reference: Manuel Martínez-Sellés et al. EuroIntervention 2015;10-online publish-ahead-of-print February 2015. Prosthesis endocarditis is a complication with serious clinical consequences due to its high morbimortality. Infective endocarditis (IE) in TAVI has been described in few cases and, in cohort studies, it occurs within 0 to...
Original title: Comparison of Transfemoral TranscatheterAortic Valve Replacement Performedin the Catheterization Laboratory(Minimalist Approach) Versus HybridOperating Room (Standard Approach). Outcomes and CostAnalysis. Reference: VasilisBabaliaros et al. J Am CollCardiolIntv 2014;7:898–904. This retrospective study of a center analyzed the results of percutaneous aortic valve replacement (TAVR) performed with a minimally invasive technique that included the closure of the femoral access...
01- TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors? In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Read also HERE 02-...
Implant depth greater than the length of the membranous septum is an independent predictor of permanent pacemaker implantation. Valve implantation 3 to 5 mm below the aortic annulus in a projection coaxial to the device is recommended. The problem is this is rarely in the annular plane of the valve. Ideal annular plane projection is...
After reports of some serious adverse events with first-generation Lotus, the device was pulled off the market—but it was not meant to be left in oblivion. Now, it is back, renewed and with the approval of the United States Food and Drug Administration (FDA), to compete directly with the two market leaders (Sapien and CoreValve),...
Courtesy of Dr. Carlos Fava. While the benefits of TAVR are well-known, the need for a permanent pacemaker after implantation is still an issue to solve, even though new valves have reduced it. This study enrolled 175 patients who underwent TAVR with an ACURATE neo TF valve. In this population, 58% of patients were women and the...